Monday, February 15, 2010

TSB Alert - Attend Tomorrow's Stem Cell Meeting in NYC.

On Tuesday, February 16th, 2010, Robin Young and the crack staff at Orthopedics This Week will hold their annual Stem Cell Symposium in New York City. As with any emerging technology, the use of stems in spinal repair, trauma, reconstructive surgery, cartilage repair and maxillo-facial procedures requires education. The purpose of this symposium is to establish a fundamental understanding of cellular therapy while providing a commercial and scientific update. At this stage TSB would like to believe that the faculty for these meetings have been able to answer what are stem cells, whether there are any risk, and how stem cells function within the human body once they are implanted.

Yet, regardless of these answers the commercial potential is staggering, and at the end of the day this is why most of the attendees come to this meeting. An estimated $1 millon dollar market in 2005, today this market is estimated somewhere in the vicinity of $300 million. A staggering fete considering where we were a mere five years ago. Today, we have numerous companies that have some type of stem cell technology that is beneficial to the patient and surgeon. Within the next few years the U.S. market for stem cell products will be defined as over 4 million procedures annually . What will the potential market value be $ 8, $10, $12 billion and what will the revenue potential be?

Well readers, if you want to know the answers to these questions, TSB recommends that you attend tomorrow's meeting. See you there.

8 comments:

  1. With due respect, after having attended one of the earlier ones, I see no reason to repeat. The one I attended had a lot of RahRah, which seems to be a RY specialty, but little real scientific, let alone clinical, facts. From my vantage point the stem cells risk going the way of so many other commercialized products in spine: many jump the bandwagon, few if any do the scientific work needed to understand, advance and improve the present state. Can you spell DBM?

    ReplyDelete
  2. I can spell DBM, that's why I write these blogs so that readers like yourself can embellish what many of us really think about these symposiums. Considering that TSB has no financial interest in these companies makes it so much easier to be objective what whether it's real or, is it Memorex. (Old technology with a new spin) Thanx for your comments

    ReplyDelete
  3. The cost of these meeting is outrageous and self-serving, that's all I have to say

    ReplyDelete
  4. The true investigators in the field of bone biology for spinal fusion know stem cells are not the answer. Stem cell products are being used by MD's for 2 reasons:
    1. They are in bed with their primary metal company who have a "product" in the bag.
    2. They glom onto every BS technology that comes around for self and practice marketing purposes.

    To MM - great site!

    ReplyDelete
  5. How was this meeting? What products were profiled?

    ReplyDelete
  6. Stem cells are the life givers of human body. There utilization in the right way will lead to many new discoveries in medical sciences. Hope this must bring some cheer to the people suffering from deadly diseases.

    ReplyDelete
  7. I just read a summary about this meeting on Ortho Spine News....interesting. Did anyone attend??? How was it? Word on the street was that is was light on spine/ortho focused companies.

    TSB what were your thoughts on this meeting and some of the technologies presented??

    ReplyDelete
  8. TSB thought that this was the best Stem Cell Meeting that Robin has had since its debut in 2006. The amount of companies that presented has multiplied tenfold, witnessed by the growth that has taken the stem cell market by storm. I was impressed by the progress that has been made by those companies that originally presented in Chicago along with the many new applications and diagnostics that are being developed. Obviously for those that did not attend this is a must meeting, regardless.

    ReplyDelete